$CLMT

Calumet stock may move 7% on upcoming earnings report

Investing.com reports Calumet Inc. (CLMT) shares may move about 7% around earnings on Aug. 7 before market open, based on Bloomberg options data. The piece notes that in 4 of the past 8 earnings, the stock’s move exceeded options-implied expectations. Historical examples are cited for 2024-2026.

Original reporting
Published Jul 31, 2026, 2:46 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 3:07 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefMarket movers
Primary signal
$CLMT
Neutral
medium confidence
Mentioned
$CLMT
Relevance
5/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$CLMTNeutralMed
01

Why it matters

Traders can use the implied-move estimate and the historical “exceeded implied” pattern to plan options spreads, hedges, and gap-risk exposure into the open.

02

Market read

This is primarily a volatility and event-timing setup for CLMT earnings, not a new fundamental catalyst.

03

What to watch

The article does not state consensus estimates, guidance content, or balance-sheet/earnings drivers, so directional positioning based solely on implied move is fragile.

Relevance 5/10Novelty 4/10Timing: ahead of Aug 7 pre-market earnings release

Background

The piece frames Calumet’s upcoming Aug 7 pre-market earnings as a volatility event using Bloomberg options-implied move history.

Company-level read

Ticker impact

$CLMTNeutralMedium confidence
Context

Calumet Inc. is set to report earnings Aug 7 pre-market, with options implying about a 7% move around the announcement.

Expected impact

Expect elevated volatility and potential gap risk near Aug 7 open; direction is uncertain from this text alone.

Evidence & confidence

The only actionable inputs are the scheduled earnings date and historical tendency for realized moves to exceed implied moves, which affects risk sizing more than directional bias.

Market effects

Limited sector read-through because the article is focused on one company’s earnings-date volatility.

No explicit regional macro or cross-market linkage provided.

No global supply chain, regulation, or cross-border catalyst mentioned.

Counterpoint

The implied-move framework can overstate realized volatility if the earnings print is closer to expectations than prior quarters.

Key entities

  • Calumet Inc.

    Subject of the article, scheduled to report earnings Aug 7 before the market opens.

  • Bloomberg options data

    Used to estimate the market-implied move around the earnings announcement.

Related articles

$CLMTMed

Why Calumet Stock Flopped on Friday

Calumet (CLMT) shares fell about 6% on Friday after its Q2 earnings showed a surprise net loss. Revenue rose to just under $1.45B, up about 41% YoY, but adjusted net loss was $95.9M, or $1.09/share, versus a year-ago deficit of $147.9M. Analysts expected profit of $0.17/share. Long-term debt exceeded $2.2B.

$CLMTMed

Calumet (NASDAQ:CLMT) Surprises With Strong Q2 CY2026

Calumet (NASDAQ:CLMT) reported Q2 CY2026 results. Revenue rose 40.8% year on year to $1.45 billion, beating Wall Street estimates by 32% (according to the article). Adjusted EBITDA exceeded consensus by 78.2%, with margin rising to 12.1%. Free cash flow was $99.35 million, turning positive after a year-ago loss.

$CLMTMed

Why Calumet Stock Was a Major Winner on Wednesday

Calumet (CLMT) shares rose more than 4% after the company said two wholly owned subsidiaries will redeem $100 million of senior notes due 2028, paying about 102.4% of par. Calumet also noted it reduced borrowings on its revolving credit facility in Q2, as part of a deleveraging plan.

$DVAMed

DaVita Shares Rise After TD Cowen Upgrades Stock to Buy

DaVita HealthCare Partners (NYSE:DVA) rose about 2.1% premarket after TD Cowen upgraded it from Hold to Buy and raised its price target to $220 from $201, citing improving competitive position and long-term growth. The upgrade followed DaVita’s Q2 2026 results: adjusted EPS $4.02 vs $3.92 expected, revenue about $3.55B vs estimates, while guidance stayed unchanged.

$ONMed

The Numbers Behind ON Semiconductor’s (ON) Higher Target and Unchanged Hold Rating

ON Semiconductor (NASDAQ:ON) reported stronger-than-expected Q2 earnings and issued Q3 guidance above Wall Street expectations. Robert W. Baird analyst Tristan Gerra raised his price target to $108 from $100 and kept a Neutral rating, citing improving AI data center, industrial, EV and China trends and gross margin guidance of 40% to 42%. He flagged potential market-share losses versus TXN and ST.